Last10K.com

Idera Pharmaceuticals, Inc. (IDRA) SEC Filing 8-K Material Event for the period ending Tuesday, May 17, 2022

Idera Pharmaceuticals, Inc.

CIK: 861838 Ticker: IDRA

View differences made from one to another to evaluate Idera Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Idera Pharmaceuticals, Inc..

Continue

Assess how Idera Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Idera Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Idera Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: IDRA
CIK: 861838
Form Type: 8-K Corporate News
Accession Number: 0001104659-22-061797
Submitted to the SEC: Tue May 17 2022 10:14:37 AM EST
Accepted by the SEC: Tue May 17 2022
Period: Tuesday, May 17, 2022
Industry: Biological Products No Disgnostic Substances
Events:
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/idra/0001104659-22-061797.htm